<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548078" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548078/" /><meta name="ncbi_pagename" content="Oxacillin - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Oxacillin - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Oxacillin" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/10/20" /><meta name="citation_pmid" content="31643408" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548078/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Oxacillin" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/10/20" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548078/" /><meta name="description" content="Oxacillin is a parenteral, second generation penicillin antibiotic that is used to treat moderate-to-severe, penicillinase-resistant staphylococcal infections. Oxacillin has been linked to rare instances of clinically apparent, idiosyncratic liver injury, but it more commonly causes transient elevations in serum aminotransferases without jaundice." /><meta name="og:title" content="Oxacillin" /><meta name="og:type" content="book" /><meta name="og:description" content="Oxacillin is a parenteral, second generation penicillin antibiotic that is used to treat moderate-to-severe, penicillinase-resistant staphylococcal infections. Oxacillin has been linked to rare instances of clinically apparent, idiosyncratic liver injury, but it more commonly causes transient elevations in serum aminotransferases without jaundice." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548078/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Oxacillin/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548078/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C7AFF04688CC10000000001040050.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548078_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548078_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Osimertinib/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Oxaliplatin/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548078_"><span class="title" itemprop="name">Oxacillin</span></h1><p class="small">Last Update: <span itemprop="dateModified">October 20, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Oxacillin.OVERVIEW"><h2 id="_Oxacillin_OVERVIEW_">OVERVIEW</h2><div id="Oxacillin.Introduction"><h3>Introduction</h3><p>Oxacillin is a parenteral, second generation penicillin antibiotic that is used to treat moderate-to-severe, penicillinase-resistant staphylococcal infections. Oxacillin has been linked to rare instances of clinically apparent, idiosyncratic liver injury, but it more commonly causes transient elevations in serum aminotransferases without jaundice.</p></div><div id="Oxacillin.Background"><h3>Background</h3><p>Oxacillin (ox" a sil' in) is a second generation penicillin that is highly resistant to inactivation by penicillinases and is used to treat moderate-to-severe bacterial infections caused by penicillinase-producing bacteria, particularly staphylococcal infections. Oxacillin was approved for use in the United States in 1989 and is still in common use. Oxacillin is indicated for moderate-to-severe bacterial infections caused by sensitive agents including acute or chronic osteomyelitis and valvular endocarditis. Oxacillin is available in both oral and parenteral preparations in several generic formulations. Parenteral oxacillin is recommended in doses of 250 or 500 mg intramuscularly or intravenously every 4 to 6 hours daily for up to 1 to 8 weeks depending upon the type and severity of infection. Oral oxacillin is recommended in doses of 500 mg every 4 to 6 hours, but is now rarely used. Common side effects include fatigue, anxiety, dizziness, diarrhea, nausea, fever and hypersensitivity reactions. Rare but potentially severe adverse events include anaphylaxis, Clostridium difficile diarrhea and neutropenia.</p></div><div id="Oxacillin.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Oxacillin has been linked to two forms of hepatotoxicity, first an acute and transient elevation in serum aminotransferase levels occurring with high doses of intravenous therapy; and second, a more prolonged, usually cholestatic, idiosyncratic liver injury that is similar to the hepatotoxicity of other second-generation penicillins such as dicloxacillin, flucloxacillin, and nafcillin.</p><p>High doses of intravenous oxacillin are commonly accompanied by elevations in serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> in the range of 2 to 20 times the upper limit of normal arising after 1 to 3 weeks of therapy. Alkaline phosphatase levels are only minimally elevated. Fever and nonspecific symptoms of abdominal pain and nausea can occur, but are often absent. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.eosinophilia/">Eosinophilia</a> is present in some patients, but rash and arthralgias are uncommon. Serum aminotransferase levels rapidly fall into the normal range (in 1 to 2 weeks) with discontinuation of oxacillin or switch to lower doses, particularly in oral formulations. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.jaundice/">Jaundice</a> does not occur. There appears to be no cross reactivity of this response with the natural penicillins, clindamycin or even nafcillin. Intravenous carbenicillin can cause a similar syndrome. This hepatotoxicity may be more common in HIV-positive than noninfected individuals.</p><p>In addition to the common syndrome of asymptomatic serum aminotransferase elevations during high dose intravenous therapy, oxacillin can also but rarely lead to a more prolonged usually cholestatic hepatitis that appears 1 to 6 weeks after starting therapy and may persist for weeks to months. This form of idiosyncratic liver injury is similar to that described with dicloxacillin and other second generation penicillins. Immunoallergic features of rash, fever and eosinophilia can occur, but are not prominent. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.autoantibodies/">Autoantibodies</a> are not found. The liver injury can be prolonged, but generally resolves within 1 to 2 months of onset. Liver biopsy generally shows a cholestatic hepatitis with mixed inflammatory infiltrates.</p><p>Likelihood score: B (likely rare cause of clinically apparent liver injury).</p></div><div id="Oxacillin.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The cause of <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations during high dose oxacillin therapy is not known, but may be due to a direct but mild injury to the liver. Fever is common, and eosinophilia and rash can occur. Liver biopsy during these episodes generally shows mild, focal cell injury. The idiosyncratic reaction to oxacillin (and other related penicillins) is rarely accompanied by signs of hypersensitivity or allergy, but has some characteristics that suggest such a mechanism, such as the rapid reappearance of injury with reexposure, and an association with a history of penicillin allergy. Too few cases of oxacillin cholestatic injury have been reported to comment on possible HLA associations, such as the link to HLA-B*5701 which has been made to flucloxacillin.</p></div><div id="Oxacillin.Outcome_and_Management"><h3>Outcome and Management</h3><p>The serum aminotransferase elevations that appear during high dose intravenous therapy with oxacillin are usually benign, asymptomatic and resolve rapidly with stopping therapy or switching to other forms of penicillinase-resistant penicillins. The cholestatic hepatitis that occurs very rarely can be symptomatic and prolonged, but has not been linked to acute, liver failure, chronic or permanent injury, or vanishing bile duct syndrome. Prednisone has been used to treat the cholestatic liver injury, but its effects are unclear while its side effects can be serious. Patients should be told to avoid reexposure to the penicillinase-resistant penicillins, including nafcillin and dicloxacillin.</p><p>Drug Class: <a href="/books/n/livertox/PenicillinSecondGen/">Penicillin (Penicillinase-Resistant)</a></p></div></div><div id="Oxacillin.CASE_REPORT"><h2 id="_Oxacillin_CASE_REPORT_">CASE REPORT</h2><div id="Oxacillin.Case_1_Elevated_aminotransfera"><h3>Case 1. Elevated aminotransferase levels during intravenous oxacillin therapy.(<a class="bk_pop" href="#Oxacillin.REF.1">1</a>)</h3><p>A 52 year old man with multiple medical problems was treated with intravenous oxacillin for suspected osteomyelitis and was found to have elevations in <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> (104 U/L) and <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> (82 U/L), with normal alkaline phosphatase and bilirubin levels when tested 7 days later. He had no symptoms that could be attributed to liver injury. Oxacillin was continued, but ALT levels continued to rise. Oxacillin was stopped after 6 weeks. Serum aminotransferase levels promptly fell and were near normal when he was discharged 2 weeks later. This patient also had multiple other medical problems including hypertension, diabetes, chronic hepatitis C, gastrointestinal reflux, chronic obstructive lung disease, depression and chronic radiculopathy for which he took many medications, none of which had been changed recently.</p><div id="Oxacillin.Key_Points"><h4>Key Points</h4><div id="Oxacillin.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548078/table/Oxacillin.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Oxacillin.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Oxacillin.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Oxacillin.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oxacillin</td></tr><tr><th id="hd_b_Oxacillin.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Oxacillin.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hepatocellular (<a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations only)</td></tr><tr><th id="hd_b_Oxacillin.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Oxacillin.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1+ (aminotransferase elevations without jaundice)</td></tr><tr><th id="hd_b_Oxacillin.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Oxacillin.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">One week</td></tr><tr><th id="hd_b_Oxacillin.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Oxacillin.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Almost complete within 2 weeks of discontinuation</td></tr><tr><th id="hd_b_Oxacillin.Tc_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Oxacillin.Tc_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Amlodipine, metoprolol, insulin, lansoprazole, levothyroxine, gabapentin, trimethoprim-sulfamethoxazole, diazepam, cyclobenzaprine, docusate, senna, iron, naproxen</td></tr></tbody></table></div></div></div><div id="Oxacillin.Laboratory_Values"><h4>Laboratory Values</h4><div id="Oxacillin.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548078/table/Oxacillin.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Oxacillin.Td_lrgtbl__"><table><thead><tr><th id="hd_h_Oxacillin.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Oxacillin.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_Oxacillin.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a><br />(U/L)</th><th id="hd_h_Oxacillin.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_h_Oxacillin.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a><br />(mg/dL)</th><th id="hd_h_Oxacillin.Td_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Oxacillin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- 1 week</td><td headers="hd_h_Oxacillin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Oxacillin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">16</td><td headers="hd_h_Oxacillin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">54</td><td headers="hd_h_Oxacillin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.7</td><td headers="hd_h_Oxacillin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Admitted with osteomyelitis</td></tr><tr><td headers="hd_h_Oxacillin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Oxacillin.Td_1_1_1_2 hd_h_Oxacillin.Td_1_1_1_3 hd_h_Oxacillin.Td_1_1_1_4 hd_h_Oxacillin.Td_1_1_1_5 hd_h_Oxacillin.Td_1_1_1_6" colspan="5" rowspan="1" style="text-align:center;vertical-align:top;">Oxacillin started: 2 grams iv every 6 hours</td></tr><tr><td headers="hd_h_Oxacillin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 days</td><td headers="hd_h_Oxacillin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Oxacillin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">104</td><td headers="hd_h_Oxacillin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">79</td><td headers="hd_h_Oxacillin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.6</td><td headers="hd_h_Oxacillin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Oxacillin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38 days</td><td headers="hd_h_Oxacillin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Oxacillin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">108</td><td headers="hd_h_Oxacillin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">92</td><td headers="hd_h_Oxacillin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.7</td><td headers="hd_h_Oxacillin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Oxacillin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40 days</td><td headers="hd_h_Oxacillin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Oxacillin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">306</td><td headers="hd_h_Oxacillin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">98</td><td headers="hd_h_Oxacillin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.7</td><td headers="hd_h_Oxacillin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Oxacillin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41 days</td><td headers="hd_h_Oxacillin.Td_1_1_1_2 hd_h_Oxacillin.Td_1_1_1_3 hd_h_Oxacillin.Td_1_1_1_4 hd_h_Oxacillin.Td_1_1_1_5 hd_h_Oxacillin.Td_1_1_1_6" colspan="5" rowspan="1" style="text-align:center;vertical-align:top;">Oxacillin stopped</td></tr><tr><td headers="hd_h_Oxacillin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43 days</td><td headers="hd_h_Oxacillin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 days</td><td headers="hd_h_Oxacillin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">318</td><td headers="hd_h_Oxacillin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">99</td><td headers="hd_h_Oxacillin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.7</td><td headers="hd_h_Oxacillin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Oxacillin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46 days</td><td headers="hd_h_Oxacillin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 days</td><td headers="hd_h_Oxacillin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">85</td><td headers="hd_h_Oxacillin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Oxacillin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Oxacillin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Oxacillin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49 days</td><td headers="hd_h_Oxacillin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 days</td><td headers="hd_h_Oxacillin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">57</td><td headers="hd_h_Oxacillin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">85</td><td headers="hd_h_Oxacillin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.6</td><td headers="hd_h_Oxacillin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Oxacillin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52 days</td><td headers="hd_h_Oxacillin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 days</td><td headers="hd_h_Oxacillin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">59</td><td headers="hd_h_Oxacillin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">80</td><td headers="hd_h_Oxacillin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.6</td><td headers="hd_h_Oxacillin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Oxacillin.Td_1_1_1_1 hd_h_Oxacillin.Td_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Oxacillin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;40</b></td><td headers="hd_h_Oxacillin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;115</b></td><td headers="hd_h_Oxacillin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Oxacillin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Oxacillin.Comment"><h4>Comment</h4><p>Oxacillin is well known to cause serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations when given in high doses intravenously. The elevations are usually mild to moderate (&#x0003c;20 fold elevated) and appear after 4 to 20 days. Most patients are asymptomatic, but complaints of abdominal discomfort or fever may arise. Alkaline phosphatase and bilirubin levels remain normal. Patients usually tolerate other intravenous antibiotics (including nafcillin) without recurrence and the injury is self-limited, not leading to jaundice or severe liver disease even if oxacillin is continued. The presence of an underlying chronic hepatitis C complicates the interpretation of this case and many of the cases in the literature. However, serum ALT levels were normal before oxacillin was started and returned towards baseline once it was stopped, making it likely that the changes were due to the drug.</p></div></div></div><div id="Oxacillin.PRODUCT_INFORMATION"><h2 id="_Oxacillin_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Oxacillin &#x02013; Generic</p><p><b>DRUG CLASS</b></p><p>Penicillin (Penicillinase-Resistant)</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Oxacillin" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Oxacillin.CHEMICAL_FORMULA_AND_STRUCTURE"><h2 id="_Oxacillin_CHEMICAL_FORMULA_AND_STRUCTURE_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Oxacillin.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548078/table/Oxacillin.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Oxacillin.Te_lrgtbl__"><table><thead><tr><th id="hd_h_Oxacillin.Te_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Oxacillin.Te_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Oxacillin.Te_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Oxacillin.Te_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Oxacillin.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oxacillin</td><td headers="hd_h_Oxacillin.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134972946" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">66-79-5</a></td><td headers="hd_h_Oxacillin.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C19-H19-N3-O5-S</td><td headers="hd_h_Oxacillin.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134972946" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134972946" alt="image 134972946 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Oxacillin.CITED_REFERENCES"><h2 id="_Oxacillin_CITED_REFERENCES_">CITED REFERENCES</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="Oxacillin.REF.1">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN).  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]</div></dd></dl></div><div id="Oxacillin.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Oxacillin_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 20 October 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Oxacillin.REF.zimmerman.1999">Zimmerman HJ. Synthetic penicillins. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999. p. 596-8.<div><i>(Expert review of penicillins and liver injury published in 1999).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.moseley.2013">Moseley RH. Hepatotoxicity of antimicrobials and antifungal agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 463-82.<div><i>(Review of hepatotoxicity of antibiotics mentions that liver injury from the penicillins is very rare, and is usually cholestatic for the oxypenicillins such as dicloxacillin and cloxacillin).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.macdougall.2018">MacDougall C. Penicillins, cephalosporins, and other &#x003b2;-lactam antibiotics. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1023-38.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.freedman.1965.34">Freedman MA. Oxacillin&#x02014;apparent hematologic and hepatic toxicity. <span><span class="ref-journal">Rocky Mt Med J. </span>1965;<span class="ref-vol">62</span>:34–6.</span> [<a href="/pubmed/14224480" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14224480</span></a>]<div><i>(33 year old woman developed AST elevations to ~220 U/L, atypical lymphocytosis and eosinophilia after 2.5 months of high dose oral oxacillin, complicated by bone marrow suppression and breakthrough in chronic osteomyelitis).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.pas.1965.674">Pas AT, Quinn EL. Cholestatic hepatitis following the administration of sodium oxacillin. <span><span class="ref-journal">JAMA. </span>1965;<span class="ref-vol">191</span>:674–5.</span> [<a href="/pubmed/14242432" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14242432</span></a>]<div><i>(65 year old woman developed itching and jaundice the week after stopping a 4 week course of oral oxacillin [bilirubin 2.2 mg/dL, Alk P ~twice elevated, AST 76 U/L], resolving within 8 weeks).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.dismukes.1973.861">Dismukes WE. Oxacillin-induced hepatic dysfunction. <span><span class="ref-journal">JAMA. </span>1973;<span class="ref-vol">226</span>:861–3.</span> [<a href="/pubmed/4800332" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4800332</span></a>]<div><i>(3 cases of ALT elevations, fever and nausea arising 11-24 days after starting high dose intravenous oxacillin therapy, with rapid reversal on stopping).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.klein.1976.546">Klein I, Tobias H. Oxacillin-associated hepatitis. <span><span class="ref-journal">Am J Gastroenterol. </span>1976;<span class="ref-vol">65</span>:546.</span> [<a href="/pubmed/961686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 961686</span></a>]<div><i>(23 year old male injection drug user developed ALT elevations [~275 U/L] without symptoms or change in bilirubin or Alk P after 10 days of intravenous oxacillin [16 g/day), with rapid resolution [&#x0003c;1 week] on stopping).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.olans.1976.835">Olans RN, Weiner LB. Reversible oxacillin hepatotoxicity. <span><span class="ref-journal">J Pediatr. </span>1976;<span class="ref-vol">89</span>:835–8.</span> [<a href="/pubmed/978335" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 978335</span></a>]<div><i>(8 instances of ALT elevations [peak values 31-1359 U/L] without jaundice [2 had eosinophilia] after 8-25 days of intravenous oxacillin in children or young adults, with rapid resolution; no recurrence when switched to nafcillin).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.bruckstein.1978.519">Bruckstein AH, Attia AA. Oxacillin hepatitis. Two patients with liver biopsy, and review of the literature. <span><span class="ref-journal">Am J Med. </span>1978;<span class="ref-vol">64</span>:519–22.</span> [<a href="/pubmed/637061" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 637061</span></a>]<div><i>(Two injection drug users treated with high dose oxacillin [12-16 g/day] for endocarditis developed increased AST levels [10-40 times ULN], with mild symptoms but no change in Alk P or bilirubin and nonspecific biopsy findings, arising after 2-3 weeks and resolving rapidly with stopping).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.goldstein.1978.171">Goldstein LI, Granoff M, Waisman J. Hepatic injury due to oxacillin administration. <span><span class="ref-journal">Am J Gastroenterol. </span>1978;<span class="ref-vol">70</span>:171–4.</span> [<a href="/pubmed/717369" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 717369</span></a>]<div><i>(21 year old male injection drug used developed aminotransferase elevations [ALT 806 U/L, AST 388 U/L, 15% eosinophils] 20 days after starting intravenous oxacillin [12 g/day], with biopsy showing hepatitis, rapid recovery).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.onorato.1978.497">Onorato IM, Axelrod JL. Hepatitis from intravenous high-dose oxacillin therapy: findings in an adult inpatient population. <span><span class="ref-journal">Ann Intern Med. </span>1978;<span class="ref-vol">89</span>:497–500.</span> [<a href="/pubmed/697229" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 697229</span></a>]<div><i>(Review of experience with high dose oxacillin revealed 8 cases of liver injury, rising 3-19 days after start of therapy with fever and mild GI symptoms, ALT 2 to 15 times ULN, Alk P minimally increased, and no jaundice; resolving in 1 week; compared to control group, a history of penicillin allergy was given in 3 cases, but not controls).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.dangelo.1979.442">D'Angelo LJ. Oxacillin and hepatotoxicity. <span><span class="ref-journal">Ann Intern Med. </span>1979;<span class="ref-vol">90</span>:442.</span> [<a href="/pubmed/426429" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 426429</span></a>]<div><i>(Letter commenting on article by Onorato &#x00026; Axelrod, without new data).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.taylor.1979.857">Taylor C, Corrigan K, Steen S, Craig C. Oxacillin and hepatitis. <span><span class="ref-journal">Ann Intern Med. </span>1979;<span class="ref-vol">90</span>:857–8.</span> [<a href="/pubmed/434706" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 434706</span></a>]<div><i>(Letter in response to Onorato &#x00026; Axelrod describing 24 year old man who developed ALT elevations [226 U/], with rash and eosinophilia after 27 days of intravenous oxacillin therapy [8 g/day], rapidly resolving upon switching to nafcillin).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.pollock.1978.915">Pollock AA, Berger SA, Simberkoff MS, Rahal JJ Jr. Hepatitis associated with high-dose oxacillin therapy. <span><span class="ref-journal">Arch Intern Med. </span>1978;<span class="ref-vol">138</span>:915–7.</span> [<a href="/pubmed/646563" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 646563</span></a>]<div><i>(Prospective study of liver tests in 41 patients during intravenous oxacillin therapy; 15 had ALT elevations, but only 5 were attributed to oxacillin, 12-23 g/day arising 5-24 days after starting, peak ALT values 5-20 times ULN, mild Alk P elevation in 4, but normal bilirubin in all, and resolution in 4-16 days of stopping; no eosinophilia, fever or symptoms).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.halloran.1979.376">Halloran TJ, Clague MD. Hepatitis associated with high-dose oxacillin therapy. <span><span class="ref-journal">Arch Intern Med. </span>1979;<span class="ref-vol">139</span>:376–7.</span> [<a href="/pubmed/426588" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 426588</span></a>]<div><i>(Letter in response to Pollock [1978] describing 16 year old girl with no history of injection drug use who developed AST elevations [peak 140 U/L], starting after 9 days of intravenous oxacillin, rapid resolution upon stopping).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.nahata.1982.117">Nahata MC, DeBolt SL, Powell DA. Adverse effects of methicillin, nafcillin and oxacillin in pediatric patients. <span><span class="ref-journal">Dev Pharmacol Ther. </span>1982;<span class="ref-vol">4</span>:117–23.</span> [<a href="/pubmed/7172968" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7172968</span></a>]<div><i>(Prospective study of children treated with intravenous methicillin [28], nafcillin [32] or oxacillin [8]; minimal ALT elevations occurred in 1 on nafcillin and 1 on oxacillin; no jaundice).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.miller.1983.465">Miller WI, Souney PF, Chang JT. Hepatic dysfunction following nafcillin and cephalothin therapy in a patient with a history of oxacillin hepatitis. <span><span class="ref-journal">Clin Pharm. </span>1983;<span class="ref-vol">2</span>:465–8.</span> [<a href="/pubmed/6627877" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6627877</span></a>]<div><i>(Mild ALT elevations after 13 days of high dose oxacillin [18 g/day], similar increase after nafcillin and again with cephalosporin in a male injection drug user with probable chronic hepatitis C, which might have accounted for ALT fluctuations).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.tauris.1985.567">Tauris P, J&#x000f8;rgensen NF, Petersen CM, Albertsen K. Prolonged severe cholestasis induced by oxacillin derivatives. A report on two cases. <span><span class="ref-journal">Acta Med Scand. </span>1985;<span class="ref-vol">217</span>:567–9.</span> [<a href="/pubmed/4025011" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4025011</span></a>]<div><i>(2 case reports: 65 year old man with osteomyelitis developed jaundice and pruritus 6 weeks after starting flucloxacillin [bilirubin ~10 mg/dL, AST 1.5 times ULN, Alk P 3 times ULN], biopsy showing cholestasis, resolving within 8 weeks of stopping; 21 year old man with osteomyelitis developed jaundice 9 weeks after starting dicloxacillin [bilirubin ~4 mg/dL, AST 119 U/L, Alk P 814 U/L], resolving within 6 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.saliba.1994.1048">Saliba B, Herbert PN. Oxacillin hepatotoxicity in HIV-infected patients. <span><span class="ref-journal">Ann Intern Med. </span>1994;<span class="ref-vol">120</span>:1048.</span> [<a href="/pubmed/8185140" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8185140</span></a>]<div><i>(Retrospective review found that 81% [9/11] of HIV-positive, but only 4.5% [3/66] of HIV-negative patients receiving iv oxacillin for more than 10 days developed ALT or AST &#x0003e;3 fold elevated).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.alhomaidhi.2002.650">Al-Homaidhi H, Abdel-Haq NM, El-Baba M, Asmar BI. Severe hepatitis associated with oxacillin therapy. <span><span class="ref-journal">South Med J. </span>2002;<span class="ref-vol">95</span>:650–2.</span> [<a href="/pubmed/12081223" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12081223</span></a>]<div><i>(6 year old girl developed fever, abdominal pain and marked ALT elevation [peak 2,257 U/L] with normal Alk P and bilirubin [0.3 mg/dL] after 14 days of intravenous oxacillin, resolving within 3 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.trevenzoli.2003.324">Trevenzoli M, Cattelan AM, Mencarelli R, Meneghetti F. Severe hepatitis associated with oxacillin therapy. <span><span class="ref-journal">South Med J. </span>2003;<span class="ref-vol">96</span>:324–5.</span> [<a href="/pubmed/12659378" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12659378</span></a>]<div><i>(Letter in response to Al-Homaidhi [2002] describing 33 year old who developed liver injury [bilirubin 1.8 mg/dL, ALT 2440 U/L, Alk P 103 U/L] weeks after receiving a 4 day course of amoxicillin/clavulanate [not oxacillin as suggested by the title]).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.ib__ez.2002.592">Ib&#x000e1;&#x000f1;ez L, P&#x000e9;rez E, Vidal X, Laporte JR. Grup d'Estudi Multic&#x000e8;nteric d'Hepatotoxicitat Aguda de Barcelona (GEMHAB). Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. <span><span class="ref-journal">J Hepatol. </span>2002;<span class="ref-vol">37</span>:592–600.</span> [<a href="/pubmed/12399224" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12399224</span></a>]<div><i>(Survey of 107 cases of acute serious liver disease, not due to viruses, found no instances of drug induced liver injury due to penicillinase-resistant penicillins).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.maraqa.2002.50">Maraqa NF, Gomez MM, Rathore MH, Alvarez AM. Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. <span><span class="ref-journal">Clin Infect Dis. </span>2002;<span class="ref-vol">34</span>:50–4.</span> [<a href="/pubmed/11731945" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11731945</span></a>]<div><i>(Retrospective analysis of laboratory tests from 222 children receiving outpatient parenteral oxacillin, nafcillin, clindamycin or other antibiotics found 12 cases of anicteric and self-limited hepatotoxicity, 9 [22%] from oxacillin, all hepatocellular with normal bilirubin, onset in 6-43 days, resolution in 1-3 weeks; none to nafcillin; 1 clindamycin, 1 ceftriaxone and 1 ampicillin/sulbactam/gentamicin).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.monshi.2013.727">Monshi MM, Faulkner L, Gibson A, Jenkins RE, Farrell J, Earnshaw CJ, Alfirevic A, et al.  Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. <span><span class="ref-journal">Hepatology. </span>2013;<span class="ref-vol">57</span>:727–39.</span> [<a href="/pubmed/22987284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22987284</span></a>]<div><i>(T cells from persons with HLA-B*57:01 were activated when exposed to dendritic cells presenting flucloxacillin bound to albumin, and were similarly activated by oxacillin, cloxacillin and dicloxacillin).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.bj_rnsson.2005.1095">Bj&#x000f6;rnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. <span><span class="ref-journal">Scand J Gastroenterol. </span>2005;<span class="ref-vol">40</span>:1095–101.</span> [<a href="/pubmed/16165719" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16165719</span></a>]<div><i>(Analysis of all fatal adverse drug event reports of liver injury in Sweden between 1966 and 2002, found 103 cases; most common causes were halothane [n=16], acetaminophen [14], flucloxacillin [9], and TMP-SMZ [6]).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.hussaini.2007.15">Hussaini SH, O'Brien CS, Despott EJ, Dalton HR. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. <span><span class="ref-journal">Eur J Gastroenterol Hepatol. </span>2007;<span class="ref-vol">19</span>:15–20.</span> [<a href="/pubmed/17206072" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17206072</span></a>]<div><i>(Review of causes of non-obstructive jaundice in 347 patients presenting between 1998 and 2004 at a single UK center, 28 were thought to be drug induced liver injury [8.1%] and antibiotics were the most common cause, 32% amoxicillin/clavulanate, 25% flucloxacillin, 18% other).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.lee.2008.146">Lee CY, Chen PY, Huang FL, Chi CS. Reversible oxacillin-associated hepatitis in a 9-month old boy. <span><span class="ref-journal">J Paediatr Child Health. </span>2008;<span class="ref-vol">44</span>:146–8.</span> [<a href="/pubmed/18307421" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18307421</span></a>]<div><i>(9 month old boy given intravenous oxacillin for septic arthritis for 8 days when he developed lethargy and marked elevations in ALT [1568 U/L], with normal Alk P and bilirubin and resolving within 10 days of switching to teicoplanin).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN).  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, antimicrobials accounted for 45% of cases with 23 single agent cases due to amoxicillin/clavulanate, 13 nitrofurantoin, 10 fluoroquinolones, 9 macrolides, 9 sulfonamides, 5 cephalosporins, 3 oxacillin, 2 doxycycline, 2 amoxicillin, and one each for gentamicin, imipenem, and clindamycin, but none from dicloxacillin or nafcillin).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.devarbhavi.2010.2396">Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. <span><span class="ref-journal">Am J Gastroenterol. </span>2010;<span class="ref-vol">105</span>:2396–404.</span> [<a href="/pubmed/20648003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20648003</span></a>]<div><i>(313 cases of drug induced liver injury were seen over a 12 year period at a large hospital in Bangalore, India; leading causes were antituberculosis agents [58%], anticonvulsants [11%] and NSAIDs [2%]; specific antibiotic agents included sulfamethoxazole/ trimethoprim [2%] and amoxicillin-clavulanate [1%]).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.ferrajolo.2010.721">Ferrajolo C, Capuano A, Verhamme KMC, Schuemie M, Rossi F, Stricker BH, Sturkenboom CJM. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. <span><span class="ref-journal">Br J Clin Pharmacol. </span>2010;<span class="ref-vol">70</span>:721–8.</span> [<a href="/pmc/articles/PMC2997312/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2997312</span></a>] [<a href="/pubmed/21039766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21039766</span></a>]<div><i>(Among 624,673 adverse drug reports in children in a worldwide pharmacovigilance database, 6595 [1%] were for hepatic injury and antibacterials accounted for 11%, those with the highest adjusted odds ratios being aztreonam, erythromycin, ceftriaxone and minocycline; no mention of penicillins).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group.  Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury including 66 due to antimicrobial agents, but none were attributed to a penicillinase-resistant penicillin).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.leitner.2010.3">Leitner JM, Graninger W, Thalhammer F. Hepatotoxicity of antibacterials: pathomechanisms and clinical data. <span><span class="ref-journal">Infection. </span>2010;<span class="ref-vol">38</span>:3–11.</span> [<a href="/pubmed/20107858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20107858</span></a>]<div><i>(Review of hepatotoxicity of antibiotics, mentions that cholestatic hepatitis has been reported with many beta-lactams and beta-lactamases inhibitors).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.bj_rnsson.2013.1419">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">144</span>:1419–25.</span> [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, including 15 due to amoxicillin/clavulanate, 1 to dicloxacillin [2nd generation] and 1 to phenoxymethylpenicillin [1st generation], the latter two cases being anicteric).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.sistanizad.2013.115">Sistanizad M, Peterson GM. Drug-induced liver injury in the Australian setting. <span><span class="ref-journal">J Clin Pharm Ther. </span>2013;<span class="ref-vol">38</span>:115–20.</span> [<a href="/pubmed/23350857" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23350857</span></a>]<div><i>(Among 17 persons with suspected drug induced liver injury seen over at 12 month period at a referral hospital in Tasmania, 11 were attributed to antibiotics including 4 to flucloxacillin, 2 amoxicillin with clavulanate, 2 amoxicillin, and 1 each to rifampin, moxifloxacin and ciprofloxacin).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.bj_rnsson.2013.1419_1">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, Presentation and Outcomes in Patients with Drug-Induced Liver Injury in the General Population of Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">144</span>:1419–25.</span> [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, including 36 [37%] due to antibiotics and specifically dicloxacillin in 1 of 22,320 patients treated and cloxacillin in 1 of 3659 patients treated).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.hern_ndez.2014.231">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al.  Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury from Latin American countries published between 1996 and 2012 identified 176 cases, of which 37 [19%] were attributed to antimicrobials, but none to penicillinase resistant penicillins such as oxacillin or dicloxacillin).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 323 cases [36%] were attributed to antibiotics 3 of which were due to oxacillin, all being self-limited episodes of aminotransferase elevations without jaundice; no instances of dicloxacillin or nafcillin associated liver injury).</i></div></div></li><li><div class="bk_ref" id="Oxacillin.REF.cirulli.2019.1707">Cirulli ET, Nicoletti P, Abramson K, Andrade RJ, Bjornsson ES, Chalasani N, Fontana RJ, et al. Drug-Induced Liver Injury Network (DILIN) investigators.  International DILI consortium (iDILIC). A missense variant in PTPN22 is a risk factor for drug-induced liver injury. <span><span class="ref-journal">Gastroenterology. </span>2019;<span class="ref-vol">156</span>:1707–1716.e2.</span> [<a href="/pmc/articles/PMC6511989/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6511989</span></a>] [<a href="/pubmed/30664875" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30664875</span></a>]<div><i>(Genome-wide association studies on 2048 patients with drug induced liver injury and 12,439 controls identified a variant in PTPN22 which was highly associated with liver injury, allele frequency being 0.12 among cases and 0.08 among controls with highest association in Northern Europeans and in cases of amoxicillin clavulanate, PTPN22 being a cellular kinase involved in modulation of immune reactions).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548078</span><span class="label">PMID: <a href="/pubmed/31643408" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643408</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Osimertinib/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Oxaliplatin/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548078&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548078/?report=reader">PubReader</a></li><li><a href="/books/NBK548078/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548078" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548078" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Oxacillin. [Updated 2020 Oct 20].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548078/pdf/Bookshelf_NBK548078.pdf">PDF version of this page</a> (132K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=oxacillin/AE+AND+Human%5BMH%5D+AND+(%20drug-induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Oxacillin: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=oxacillin" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Oxacillin: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4857446" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4857446" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4857446" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643722" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nafcillin</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nafcillin<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/978335" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Reversible oxacillin hepatotoxicity.</a><span class="source">[J Pediatr. 1976]</span><div class="brieflinkpop offscreen_noflow">Reversible oxacillin hepatotoxicity.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Olans RN, Weiner LB. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Pediatr. 1976 Nov; 89(5):835-8. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643436" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dicloxacillin</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dicloxacillin<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/14140755" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">THE ROLE OF PENICILLINASE IN STAPHYLOCOCCAL INFECTIONS.</a><span class="source">[Br J Exp Pathol. 1964]</span><div class="brieflinkpop offscreen_noflow">THE ROLE OF PENICILLINASE IN STAPHYLOCOCCAL INFECTIONS.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">SHILO M, CITRI N. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Br J Exp Pathol. 1964 Apr; 45:192-7. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/14254395" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">[METHICILLIN- AND OXACILLIN-RESISTANT STAPHYLOCOCCI].</a><span class="source">[Munch Med Wochenschr. 1964]</span><div class="brieflinkpop offscreen_noflow">[METHICILLIN- AND OXACILLIN-RESISTANT STAPHYLOCOCCI].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">STILLE W, HIRSCH HA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Munch Med Wochenschr. 1964 Aug 28; 106:1528-32. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643408" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643408" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60468d50ddcb804c591b6d33">Oxacillin - LiverTox</a><div class="ralinkpop offscreen_noflow">Oxacillin - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T15:47:12-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal105&amp;ncbi_phid=CE8C7AFF04688CC10000000001040050&amp;ncbi_session=CE8C7AFF0468D4F1_0260SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548078%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548078&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548078/&amp;ncbi_pagename=Oxacillin - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C7AFF0468D4F1_0260SID /projects/books/PBooks@9.2 portal105 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>